Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24365687 | 1.00 | PIK3CD (0.41) | PIK3CDABL1FGFR1FGFR2FGFR3 | |
| SCHEMBL29477676 | 0.92 | PIK3CD (0.46) | PIK3CDCDK8RIPK2 | |
| SCHEMBL30551259 | 0.92 | PIK3CD (0.46) | PIK3CDCDK8RIPK2 | |
| SCHEMBL24365179 | 0.92 | PIK3CD (0.46) | PIK3CDCDK8RIPK2 | |
| SCHEMBL25322160 | 0.92 | PIK3CD (0.46) | PIK3CDCDK8RIPK2 | |
| SCHEMBL29081927 | 0.83 | RET (0.35) | PIK3CDAURKAPDPK1AURKB | |
| SCHEMBL29081206 | 0.83 | NAMPT (0.42) | PIK3CDABL1IDO1TDO2ACACB | |
| SCHEMBL24364960 | 0.82 | TRPA1 (0.36) | PIK3CDIDO1TDO2ACACBNAMPT | |
| SCHEMBL29477737 | 0.82 | TRPA1 (0.36) | PIK3CDIDO1TDO2ACACBNAMPT | |
| SCHEMBL31578394 | 0.82 | NR1H2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PIK3CD 4481/4885ABL1 875/4885FGFR1 1388/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | PIK3CD 3800/4885ABL1 2172/4885FGFR1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.